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“The important thing is not to stop 
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ABSTRACT 
Myxoid liposarcoma (MLS) is characterised by the FUS-DDIT3, or the less common 
EWSR1-DDIT3 fusion oncogene and is the second most common type of liposarcoma. 
The fusion oncogenes encode chimeric transcription factors that are causal factors in 
tumourigenesis however, their functions are poorly known. Notwithstanding 
continuous progress in treating MLS patients, existing therapies suffer from a major 
flaw as they do not target the cancer stem cells (CSCs). Unique features of CSCs 
include self-renewal, tumour initiating capacity and increased resistance to radiotherapy- 
and chemotherapy-induced cell death. Thus, CSCs are crucial targets for successful 
therapy. The aims of this project were to define the role of fusion oncogenes in 
tumourigenesis and to define signalling pathways controlling CSC features in MLS. 
Here, we demonstrated that MLS has an intact TP53 system that may explain why this 
tumour entity is genetically stable. We investigated the regulatory mechanisms, 
expression levels and effects of FUS-DDIT3 in detail, and showed that FUS-DDIT3 
was uniquely regulated at both transcriptional and post-translational level. We also 
screened 70 well-characterised kinase inhibitors and determined their effects on cell 
proliferation and FUS-DDIT3 expression at mRNA and protein levels. To facilitate 
these studies, we developed a novel direct lysis approach that enables us to quantify, 
cell proliferation, mRNA and protein expression in the same sample. This method 
allowed us to identify a number of previously unknown signalling pathways that 
regulated the expression of FUS-DDIT3. To study cell division and growth in detail, we 
applied single-cell analysis on unsynchronized cells at different cell cycle phases and cell 
sizes. We found that the total transcript level per cell and the expression of most 
individual genes correlated with progression of the cell cycle, but not with cell size. 
Detailed studies of cell cycle predictive genes revealed a previously unknown G1 
subpopulation. Finally, we showed that MLS contains cells with CSC features and that 
JAK-STAT signalling controls their numbers. Leukaemia inhibitory factor stimuli 
increased the number of CSCs, while JAK inhibition depleted the CSC pool. Inhibition 
of JAK-STAT also showed synergistic effects when combined with chemotherapy in 
vitro. Our findings concerning FUS-DDIT3 function and CSCs have increased our 
molecular understanding of tumour development and therapy resistance in MLS that 
will facilitate development of specific treatment strategies.  
Keywords: FUS, FUS-DDIT3, myxoid liposarcoma, cancer stem cells, JAK-STAT 
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Sammanfattning på svenska 
Myxoid liposarkom (MLS) är en cancertyp som oftast utvecklas i kroppens mjukdelar, 
främst i muskelvävnad. MLS karaktäriseras molekylärt av en genetisk förändring där två 
kromosomer felaktigt sammanfogas och bildar en ny gen, en så kallad fusionsgen. Den 
vanligaste sjukdomsdrivande fusionsonkogenen i MLS är FUS-DDIT3, men även 
EWSR1-DDIT3 förekommer. Utöver fusionsonkogenen har MLS, till skillnad från 
många andra tumörtyper, inte många genetiska förändringar. Dessa fusionsonkogener 
ger upphov till abnormala proteiner som kan styra uttrycket och funktionen av andra 
gener och är på så sätt viktiga för tumörbildningen. Trots denna centrala roll i MLS så 
är fusionsonkogenernas funktion dåligt kartlagd.  
Tumörer innehåller flera olika typer av cancerceller och man tror att det finns en 
ovanlig typ, cancerstamcellerna, som är extra viktiga för tumörens utveckling och 
behandlingsresistens. Trots ständig utveckling av behandlingsmetoder för MLS så finns 
det inga som är direkt riktade mot dessa potentiellt mycket farliga cancerstamceller.  
Syftet med detta arbete var att definiera fusionsonkogenernas roll i tumörbildning samt 
att definiera de signalvägar som kontrollerar cancerstamcellernas egenskaper i MLS. 
Först visade vi att MLS oftast har ett välfungerande TP53-system vilket skyddar 
cancercellerna från att få fler mutationer och därmed gör dem genetiskt stabila. Vi har 
också kartlagt de mekanismer som styr mängden av fusionsonkogenen FUS-DDIT3 på 
både transkript- och proteinnivå. Vidare så utvecklades även en metod för att kunna 
analysera uttryck av transkript, protein samt celltillväxt i ett och samma prov. Denna 
metod använde vi för att identifiera signalvägar som påverkade både celltillväxt och 
uttryck av FUS-DDIT3 i MLS via behandling med olika droger.  
Cellcykeln är ofta påverkad i cancer och vi studerade detta genom att analysera enskilda 
MLS-celler i olika cellcykelfaser. Vi visade att den totala nivån av transkript i cellerna 
ökade när cellerna förflyttade sig genom cellcykeln. Vi upptäckte även att det fanns två 
olika typer av celler i den första cellcykelfasen. Slutligen så kunde också identifiera att 
en signalväg kallad JAK-STAT reglerade mängden cancerstamceller i MLS. Genom att 
blockera denna signalväg med en specifik drog kunde vi minska antalet 
cancerstamceller i MLS, speciellt i kombination med en i MLS vanligt förekommande 
cellgiftsbehandling.  
Våra upptäckter gällande funktionen av FUS-DDIT3 och cancerstamceller i MLS ökar 
kunskapen gällande tumörutveckling och behandlingsresistens i denna sjukdom vilket 
möjliggör att mer effektiva och specifika behandlingsstrategier kan utvecklas. 
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Introduction 
Cancer  
   Cancer is a heterogeneous group of diseases characterised by immortalised and 
proliferative cells, which are growing in an uncontrolled manner and is a major cause of 
death worldwide. Its incidence is primarily associated with increased age even though 
cancer occurs in all age groups, including children and young people 1. Cancer 
originates from a single normal cell that has received several mutations and features, 
termed ”hallmarks of cancer” 2. In 2000 Hanahan and Weinberg proposed six essential 
hallmarks of cancer: sustaining proliferative signalling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, and 
activating invasion and metastasis. In 2011, two new additional hallmarks, reprograming 
of energy metabolism and evading immune destruction, were proposed to be involved 
in pathogenesis of cancer 3. Full transformations of normal cells to a neoplastic state 
require multistep alterations of all eight stated hallmarks, however, the mechanism, 
order and time scale of these changes varies between individual malignancies. The term 
tumour and cancer are widely used in many publications without stating that the 
tumours are not invasive or metastatic. Hence, the forms of cancer that invade into 
surrounding tissues and metastasise to distant sites in the body are referred as malignant 
tumours 4. In contrast, the term benign tumour (non-cancerous tumour) refers to 
abnormal cells that do not invade or metastasise to the surrounding area of the body 
and, in general, grow slowly 5. Thus, the proposed hallmarks of cancer with the 
exception of ‘’invasion and metastasis’’, are also characteristics of benign tumours.  
   Malignant tumours are categorized by the type of cells that the tumours originate 
from. Tumours that arise from epithelial tissues are classified as carcinoma. The 
remaining tumours arising from non-epithelial cells are categorized into: lymphoma and 
leukaemia which are derived from hematopoietic cells, neuroectodermal tumours 
derived from the central and peripheral nervous system, and sarcomas derived from 
mesenchymal cells. Sarcoma is a rare and heterogeneous group of malignant tumours, 
arising in or from bone and connective tissues such as muscle, fat, peripheral nerves, 
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fibrous, or other tissues supporting the body 6, 7. The histopathological spectrum of 
sarcomas is broad, and based on their cells of origin they are divided into different 
types such as osteosarcoma (osteoblasts), leiomyosarcoma (smooth muscle cells), 
fibrosarcoma (fibroblasts) and liposarcoma (adipocytes) 8.  
   Today, cancer is usually treated with surgery, radiation and chemotherapy. Despite an 
improved survival of patients standard therapies have major shortcomings as they are 
unspecific and cause many unwanted side effects. Hence, immune-, endocrine- and 
targeted therapies have been developed. However, therapy responses are still often 
temporary. To overcome therapy failures we need to have better understanding of the 
complex tumours and the mechanisms involved in tumour initiation and development, 
which eventually will allow the development of tumour-specific treatments with few 
side effects.  
Myxoid liposarcoma  
   Sarcomas account for less than 1 percent of all adult malignancies and 12 percent of 
pediatric cancers 9-11. Liposarcomas, which are categorized in three subtybes; well-
differentiated, pleomorphic and round-cell/ myxoid liposarcoma (MLS), account for 15 
to 20 percent of all sarcomas, making them the most common type of sarcoma in 
adults 12. The Scandinavian Sarcoma Group has reported that liposarcomas constitutes 
17.5 percent of all registered sarcomas (5837 patients) from 1987 through 2011 13. MLS 
is the second most common liposarcoma subtype that constitutes about 10 percent of 
all adult soft tissue sarcomas. MLS grows in the deep soft tissue, including muscle and 
fat of the extremities, and the majority of cases occur in the thighs. Histologically, MLS 
tissue is composed of uniform round to oval-shaped mesenchymal cells. MLS is notable 
for a high abundance of extracellular matrix with myxoid appearance and relatively 
sparse cellular components, set in a myxoid matrix with a fine piped capillary network 
(Fig. 1) 14, 15. In addition to histological criteria, MLS is characterised by its karyotypic 
hallmark, the chromosomal translocation t(12;16)(q13;p11) that results in a fusion 
oncogene arrangement between FUS and DDIT3 (90 percent of the cases). In rare 
cases, an alternative translocation event occurs, t(12;22)(q13;q12), that results in an 
EWSR1-DDIT3 fusion oncogene 16. Approximately, one third of all MLS patients 
develop distant metastasis with special tendency to recur in extrapulmonary sites such 
as retroperitoneum (anatomical space in abdominal cavity behind the peritoneum), 
opposite extremity, axilla, and bone 17. In a subset of cases, the cellularity increases with 
a predominance of round cells containing a high nuclear to cytoplasmic ratio and clearly 
visible nucleoli. MLS with more than 5 percent of cells presenting round cell 
characteristics is associated with a worse clinical outcome, since they are considered to 
be aggressive with high risk to develop metastases 18. 
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Figure 1. Immunohistochemistry of myxoid liposarcoma. A typical MLS morphology is 
shown. MLS is characterised by a large myxoid extracellular matrix, low cell density and a 
fine piped capillary network. The tumour contains several cell types, where most cells display 
a mesenchymal phenotype, but lipoblasts are also commonly observed.  
   Surgery is the most common treatment for localized, primary MLS. In patients with 
advanced or metastatic disease, radiation and cytotoxic chemotherapy are used 19. The 
most commonly chemotherapeutic drugs used for treatment of MLS are trabectedin, 
doxorubicin and a combination of doxorubicin and ifosfamide 20, 21. The combination 
of doxorubicin and ifosfamide has resulted in a synergistic response rate of 43 percent 
in MLS 22. Despite the success of using chemotherapy to treat MLS, chemotherapy is 
not beneficial for all patients and is also associated with high toxicity and side effects, 
such as neutropenia (low concentration of neutrophils in the blood), nausea (sickness 
of the stomach), and anaemia (low amount of red blood cells) 20, 23. Hence, new specific 
treatments are needed that target genuinely malignant subsets of cancer cells. 
The genetics of myxoid liposarcoma 
Fusion oncogenes 
   Chromosome abnormalities have an important role in the initiation of human cancer. 
Chromosomal translocations are considered as primary causes for many cancers, 
including hematopoietic, lymphoid and solid tumours 24. An oncogenic chromosomal 
translocation can broadly have two consequences. One is to generate oncogenic fusion 
proteins, formed by fusion of two genes with breakpoints located within protein coding 
regions. An example of this mechanism is the BCR-ABL oncoprotein formed as a 
result of chromosomal translocation t(9;22)(q34;q11) in chronic myeloid leukaemia 25. 
The second mechanism is a juxtaposition of the coding region of a gene near the 
transcriptionally active promoter or enhancer region of another gene, hence leading to 
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their altered expression. The overexpression of the proto-oncogene c-MYC as a result 
of the juxtaposition of c-MYC to the regulatory element of immunoglobulin heavy 
chain in Burkitt lymphoma is a classic example of this second mechanism of oncogenic 
chromosomal translocation 24. The use of advanced sequencing techniques during the 
past decade has revealed numerous gene fusions in various cancer types. Gene fusions 
occur in the majority of lymphomas, over half of leukaemias 26, and in one third of soft 
tissue tumours 27. The probability that a tumour is formed as a result of fusion 
oncogenes depends on several factors, including the fusion oncogene mutation rate, cell 
type, and accumulation of additional genetic and/or epigenetic changes 28. The majority 
of discovered fusion oncogenes encode abnormal transcription factors, while a minority 
express chimeric proteins that deregulate growth factor signalling 29, 30.      
   Interestingly, a large number of sarcoma fusion oncogenes have shown to be tumour-
type specific. Three models may describe this specificity; (i) a cell type-specific 
mechanism for chromosomal rearrangements, (ii) cell/tissue-type dependence for 
survival/oncogenic activity, and (iii) phenotype-instructive activity of the fusion 
oncogene 31-35. In some tumours, including MLS, the fusion oncogenes may be the only 
observed mutation. Several of these fusion oncogenes have also been shown to have 
the capacity to transform cells in culture and to form tumours in transgenic mice, 
indicating that the fusion oncogenes have an “instructing master activity” that 
differentiates the cell towards a specific cell fate 36. These properties of fusion 
oncogenes suggest their importance in tumour initiation and development and their 
importance as diagnostic and prognostic biomarkers. Fusion oncogenes are also 
considered to be powerful therapeutic targets, supported by data showing that targeting 
fusion oncogenes cause cell death and decreased proliferation 37, 38.  
FET family of fusion oncogenes  
   The FET group (FUS, EWSR1 and TAF15) of fusion oncogenes are found in human 
sarcomas and certain leukaemias 28. MLS and Ewing sarcoma are the two most 
common entities, while the other tumour types are extremely rare. All three genes 
(FUS, EWSR1 and TAF15) form fusion oncogenes with different transcription factors 
as a result of chromosomal translocations (Fig. 2). These mutations cause the N-
terminal domain of FUS, EWSR1 or TAF15 to become juxtaposed to the C-terminal 
parts of various transcription factors, thereby forming abnormal chimeric transcription 
factors.  
   The FET family genes encode proteins with comprehensive structural similarities that 
share a number of highly evolutionarily conserved regions including an N-terminal 
serine-tyrosine-glycine-glutamine rich sequence, variable number of arginine-glycine-
glycine repeats, G-rich regions, a zinc finger domain, and a 87-amino acid RNA 
recognition motif (Fig. 3) 39. FET proteins are ubiquitously expressed in all cell types 
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and are involved in: (a) transcriptional regulation by binding to both eukaryotic RNA 
polymerase II and transcription factor II 40, (b) microRNA (miRNA) processing by 
modulating the activity of the Drosha microprocessor complex which is required for 
miRNA biogenesis 41, 42, (c) pre-mRNA splicing due to interactions with various 
splicing and transcription factors 43, 44, (d) RNA transport in which FET proteins in 
complex with heterogeneous nuclear ribonucleoproteins (hnRNPs) shuttle between 
nucleus and cytoplasm 45, (e) translation 46, and (f) DNA repair, as they promote 
homologous DNA pairing and DNA D-loop formation 47. 
 
 
 
Figure 2. FET sarcomas and leukaemias are characterised by fusion oncogenes. FUS, 
EWSR1 and TAF15 (inner circle) form fusion oncogenes with specific transcription factor 
genes (outer circle). The latter determines the tumour entity. The common fusion oncogenes 
for respective tumour entity are shown.  
FUS-DDIT3  
   Earlier research of chromosome analysis has identified the t(12;16)(q13;p11) 
translocation, resulting in the FUS-DDIT3 fusion oncogene in MLS. Depending on the 
location of the fusion genetic breakpoints, different isoforms of the FUS-DDIT3 fusion 
transcript are formed. Type I and II fusion transcripts are the most common isoforms 
generated by alternative splicing of exon 5 or 7 of the FUS gene to exon 2 of the 
DDIT3 gene 48. The FUS-DDIT3 chimeric gene encodes a protein that functions as an 
aberrant oncogenic transcription factor (Fig. 3).  
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   The FUS-DDIT3 protein is localised to the nucleus. In most FUS-DDIT3 forms, the 
central and the C-terminal domains of FUS are lost and replaced by the entire DDIT3 
protein. Our group has previously identified an evolutionarily conserved N-terminal 
motif (FET binding motif, FETBM1) in all FET protein that mediates binding of the 
full-length FET proteins in homo- and heterocomplexes (Fig. 3B) 49. The binding motif 
is retained in all FET fusion oncoproteins, mediating the binding of the fusion 
oncoprotein to all three normal FET proteins. This binding site is believed to play an 
important role in transcription factor activity of FUS-DDIT3 49.   
 
Figure 3. Chromosomal translocation t(12;16)(q13;p11) and FUS-DDIT3 protein domains. 
(A) The chromosomal translocation t(12;16)(q13;p11) forms the fusion oncogene FUS-
DDIT3. In FUS-DDIT3, the N-terminal part of FUS is fused to the entire DDIT3. (B) The 
FUS protein domain contains a 26-amino acids long FET binding motif, a serine-tyrosine-
glycine-glutamine (SYGQ)-rich region, an argenine-glycine-glycine (RGG) region, an RNA 
recognition motif (RRM), and a zing finger (ZF) domain. DDIT3 contains DNA-binding 
domain (DBD) and leucine zipper (LZ) domain structures. All FUS-DDIT3 forms contain the 
FET binding motif and SYGQ domains of FUS and both DDIT3 domains. The breakpoints for 
three different FUS-DDIT3 forms (Type I, II and VI) are shown. 
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   DDIT3 determines the tumour entity, while the N-terminal part of FET proteins may 
replace each other whilst giving rise to the same tumour type (Fig. 2) 50. Expression of 
FUS-DDIT3 in transgenic mice has been shown to develop MLS-like phenotype in 
adipose tissue only, indicating the sensitivity of certain target cells for the action of 
FUS-DDIT3 36. Furthermore, in another study it has been shown that FUS-DDIT3 has 
the ability to transform mesenchymal stem cells to MLS-like tumour cells. In contrast 
to the previous study, the used transgenic mice model required inactivation of TP53 to 
form tumours 51. FUS-DDIT3 commits mesenchymal progenitor cells to the adipocyte 
lineage, followed by blockage of terminal differentiation of preadipocytes 31, 51. 
Termination of adipocyte differentiation at the transcriptional level occurs by 
interaction of FUS-DDIT3 with proliferator-activated receptor-γ 2 (PPARγ2) and 
CCAAT-enhancer-binding protein-α (C/EBPα), two key players in terminal adipocyte 
differentiation. It is known that normal DDIT3 forms heterodimers with other 
CCAAT-enhancer-binding protein members and this capability is preserved by the 
oncogenic FUS-DDIT3 protein. Therefore, the DDIT3 domain of the fusion 
oncoprotein is thought to be responsible for blockages of adipocyte differentiation 52-54. 
In conclusion, the cell or origin for MLS initiation is believed to be a mesenchymal 
stem cell, but the exact nature of this tumour initiating cell remains unknown, especially 
in human. 
Cell cycle regulation in myxoid liposarcoma 
   The cell cycle control system is the regulatory network that controls the order and 
timing of the cell cycle. Cyclin-dependent kinases (Cdks) which govern distinct cell-
cycle events are key components of the cell cycle. Mammalian cells have nine Cdks, of 
which only four (Cdk1, 2, 4 and 6) are involved in the cell cycle, and their enzymatic 
activation requires their binding to cyclin subunits. In most cases, full Cdk activation 
requires phosphorylation of its threonine residues by Cdk-activating kinases. Cyclins are 
divided into 4 groups, based on the timing of their expression: G1/S (cyclin E), S 
(cyclin A), and M (cyclin B) cyclins, which are involved in cell-cycle control, and G1 
cyclins (cyclin D) which controls cell-cycle entry (Fig. 4). The activity of cyclin-Cdk 
complexes is regulated by the addition or removal of inhibitory phosphorylation and by 
the expression level of various Cdk-inhibitory proteins that, by binding to cyclin-Cdk 
complexes, causes inactivation of cell cycle complexes. Cdk-inhibitory proteins are 
important for G1 cell-cycle arrest during unfavourable situations or when DNA 
damage occurs. CDKN1B (P27) and CDKN1A (P21) are two examples, which inhibit 
both cyclin E-Cdk2 and cyclin A-Cdk2 complexes.  
   In MLS, a substantial proportion of tumour cells are senescent 55. Cellular senescence 
refers to permanent and irreversible cell-cycle arrest without undergoing cell death that 
otherwise may occur when cells experience oncogenic stress 56. Senescent MLS cells are 
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characterised by the expression of certain cytokines and cytokine receptors as well as an 
increase in the expression of heterochromatin protein 1 gamma (HP1𝛾𝛾) and 
retinoblastoma-like 2 protein (RBL2). All are involved in cell cycle regulation and 
maintenance of cell senescence 14. Low expression of proliferation marker Ki67 also 
indicates a low cell division rate and mitotic activity of MLS cells 14, 57.   
 
Figure 4. Cell-cycle control system. The concentration of three main cyclins during the cell-
cycle phases are shown.  
   Normal DDIT3 causes G1/S arrest in stress conditions and prevents cells from 
progressing throughout the cell cycle. In contrast, FUS-DDIT3 expression does not 
mediate growth arrest 58, even if FUS-DDIT3 induction in vitro and in vivo has been 
shown to decrease growth rate, increased senescence and even caused cell death 59. 
FUS-DDIT3 deregulates the expression of target genes such as growth-controlling 
genes. Previous studies of cell cycle regulating proteins in MLS revealed abnormal 
expression patterns of several cell cycle controlling proteins. Cyclins D1 and E together 
with their associated kinases Cdk4 and Cdk2, which are associated with the G1 cell-
cycle phase, are strongly overexpressed in all MLS tumours. At the same time, cyclin A, 
which is specific for the S and G2 phases of the cell cycle, is lowly expressed in these 
tumours 57. Additionally, Cdk inhibitors CDKN2A (P16), CDKN2D (P19) and 
CDKN1B (P27) are also highly expressed together with G1 cyclins-Cdk complexes. 
Hence, a deregulated cell-cycle possibly plays an important role in the pathogenesis of 
MLS. Defining the mechanisms and understanding whether the specific FUS-DDIT3 
fusion oncogene is directly involved in deregulation of the cell cycle requires the 
analysis of individual cell cycle regulators in more detail.  
Cancer stem cells and tumour heterogeneity  
   Tumours, including MLS, display large inter- and intraheterogeneity with multiple cell 
types that display different phenotypes and genotypes. Numerus factors, including 
genetic and epigenetic changes as well as the microenvironment, contribute to tumour 
cell heterogeneity. The clonal evolution and cancer stem cell (CSC) models are two 
theories that have been postulated to account for intratumoural heterogeneity. The 
clonal evolution model is a non-hierarchical tumour development model where genetic 
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and epigenetic aberrations during tumour development result in a selective growth 
advantage for specific cells that contribute to tumour development. Conversely, the 
CSC model suggests a hierarchical manner where a small subset of cells (CSCs), are 
capable to sustain tumourigenesis and to generate heterogeneity through different 
degrees of differentiation. The CSC model, at least to some degree, mimics the cell 
hierarchy observed in normal development (Fig. 5) 60, 61. 
   CSCs refer to a subset of tumour cells that has the ability to self-renew and generate 
the distinct cells that constitute the tumour. These cells have been termed CSCs to 
reflect their ‘stem-like’ features and tumourgenic capabilities 62. CSCs are low 
proliferative cells with the tendency to resist therapy and they are responsible for 
tumour initiation, progression and metastasis 63. CSCs have been shown to be 
associated with aggressive disease, poor prognosis and therapy relapses. Thus, 
characterisation and elimination of CSCs is crucial in patient treatment 64. 
 
Figure 5. Tumour heterogeneity and theoretical models. The clonal evolution (left) and the 
cancer stem cell (right) models are illustrated. A third concept is a combination of these two 
models. 
   Al-Hajj and co-workers were the first to identify CSCs in solid tumours 65. After that, 
CSCs have been identified in various tumour entities, such as melanoma 66, 
glioblastoma 67, prostate cancer 68 and lung cancer 69. As mentioned earlier, CSCs are 
quiescent or slowly dividing cells and this feature of CSCs might potentially be one of 
the mechanisms by which CSCs resist therapy. The currently developed therapeutic 
agents generally target proliferative cells. Thus, CSCs can survive therapy and remain 
vital to regenerate the tumour 64. Another mechanism by which CSCs resist therapy is 
through the expression of adenosine triphosphate-binding cassette (ABC) transporters. 
ABC transporters are complex molecular pumps that are able to efflux a wide range of 
substrates from the cells by the hydrolysis of adenosine triphosphate (ATP) 70. Elevated 
expression of ABCB1, ABCG2 and ABCC1 proteins is associated with drug resistance 
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in several tumour types, such as breast cancer, lung cancer, acute myeloid leukaemia 
and pediatric sarcoma 71-73. Furthermore, CSCs have an enhanced DNA repair capacity, 
which is yet another mechanism of therapy resistance 74. All these properties of CSCs 
contribute to therapy resistance. Hence, improved understanding of CSC functions and 
properties are essential to develop better targeted treatment strategies. 
Isolation and characterisation of cancer stem cells  
   Identification and isolation of CSCs can be performed with different methodologies. 
CSC enrichment using the expression of specific surface markers is today a widely used 
approach. One of the first reported strategies was demonstrated in leukaemia, where 
CSCs were isolated by collecting CD34+ and CD38- cells 75. Since then CSCs have been 
enriched using different sets of cell surface markers, including CD20, CD24, CD34, 
CD44, CD90, CD117 and CD133, in various tumour entities 76. Despite the successful 
use of CSC surface markers, several studies have shown that most markers are not 
always expressed by all CSCs of the same tumour type 77, 78. In addition, the expression 
of CSC surface markers are affected by various factors 61, 79. Hence, it is important to 
consider several biological and technical aspects when using antibodies targeting CSC 
surface markers, including using other isolation techniques. If possible, multiple 
isolation techniques may be applied to increase specificity and limit the possibility to 
miss subpopulations of CSCs.  
   Cancer stem cells can also be isolated based on their functional properties using the 
aldehyde dehydrogenase (ALDH) assay, the side population (SP) discrimination assay 
and the non-adherent sphere formation assay 61. Previous studies have shown that 
ALDH plays an important role in stem cell biology and therapy resistance. These 
studies have shown that cells with high ALDH activity are highly associated with 
enhanced tumourigenicity and CSC characteristics 80. However, ALDH activity is 
problematic to be detected in numerous tissues, ALDH exists in multiple isoforms and 
chemotherapy may influence their activity. Hence, ALDH activity is not always a 
universal CSC marker 81, 82. 
   The SP discrimination assay is an in vitro method to identify CSCs based on their 
ability to efflux Hoechst dye staining via the ABC protein family. In this method, CSCs 
subsequently efflux the loaded Hoechst DNA binding dye out of the cell membrane 
using ABC transporters, whereas non-CSCs retain the dye. Identified SP cells can 
undergo asymmetric division generating both SP and non-SP populations. In addition, 
SP cells have displayed an increased capacity of self-renewal and tumourigenicity when 
transplanted into immune-deficient mice 83-85. Consequently, the existence of a SP 
phenotype may explain why tumours contain subpopulations that display chemotherapy 
resistance 70, 86. However, it is important to note that not all tumours contain SP 
populations. Therefore, SP cells may define one specific type of CSCs. 
11 
 
   The non-adherent condition assay (sphere formation assay) is another in vitro assay 
that has been adapted for the quantification of stem cell activity and self-renewal 87. 
Stem and progenitor cells can grow and form spherical structures in serum-free 
medium in non-adherent culture conditions when seeded as single-cells. These cells are 
equipped with the unique feature to avoid anoikis in order to overcome apoptosis 
signalling. Observation of enriched SP fractions, CSC surface markers and expression 
of pluripotency associated markers in sphere cells compared to non-sphere cells 
demonstrates that the sphere formation assay can provide a functional in vitro tool to 
investigate pathways involved in stem/progenitor cell survival 88. 
The JAK-STAT signalling pathway 
   The Janus kinase-signal transducers and activators of transcription (JAK-STAT) 
pathway is an intracellular signal transduction cascade linking extracellular cytokines, 
interleukins and growth factors with nuclear gene transcription 89. The JAK-STAT 
pathway is involved in many physiological processes including cell proliferation, 
differentiation, cell migration, survival, apoptosis, development and inflammation 90, 91. 
Activation of JAK-STAT pathway occurs when any from a variety of ligands bind to 
transmembrane receptors families. Ligand-receptor binding produces conformational 
changes in their receptors, causing hetero- or homo-dimerization of receptor subunits. 
This multimerization of receptors brings two JAKs into close proximity allowing them 
to phosphorylate each other. The activated JAKs subsequently phosphorylate tyrosine 
residues in the cytoplasmic tails of the receptors, creating binding sites that recruit 
STATs. Once STATs are bound to the receptors, JAKs can phosphorylate STATs (p-
STAT) on tyrosines, causing the STATs to dissociate from the receptor. Activated 
STATs then forms dimers that translocate to the nucleus and binds to specific 
enhancer elements 92-94 (Fig. 6). Negative regulators that are divided in three major 
classes: protein tyrosine phosphatases, protein inhibitors of activated STAT (PIAS) and 
suppressors of cytokine signalling (SOCS), modulate the activation of the JAK-STAT 
signalling pathway at multiple levels 92. Protein tyrosine phosphatases remove 
phosphate groups from both JAKs and STATs. Protein inhibitors of activated STAT 
(PIAS) inhibit the DNA binding of STATs, control STAT cellular localisation and 
assist post-translational modification of STATs 93. Suppressors of cytokine signalling 
(SOCS) inhibit the JAK-STAT signalling through three mechanisms: (i) blocking the 
recruitment of STATs, (ii) inhibiting JAK kinase activity by binding to the 
phosphorylated JAKs and their receptors and (iii) by acting as ubiquitin ligases and 
thereby causing degradation of JAK-STAT components with proteasomes 92, 95. 
   The mammalian JAK family has four members, JAK1-3 and Tyk2. JAK1, JAK2 and 
Tyk2 are ubiquitously expressed, whereas expression of JAK3 is mainly found in the 
haematopoietic system 95, 96. JAKs have unique structures compared to other protein 
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tyrosine kinases and are composed of seven regions of conserved homology, known as 
JAK homology domains (JH1-JH7). The mammalian STAT family comprises seven 
structurally and functionally related proteins: STAT1-4, STAT5A, STAT5B and 
STAT6. As a result of specific ligand-receptor activation distinct dimers of active 
STATs can be generated 97, 98. Various cytokine receptors can act via the JAK-STAT 
pathway. Interleukin 6 (IL6) family of cytokines compromises IL6, IL11, leukaemia 
inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), 
cardiotrophin-1 (CTF1) and cardiotrophin-like cytokine (CLC) 99. The IL6-type 
cytokines activate the JAK-STAT signalling pathway via signal transducers glycoprotein 
130 (GP130, also known as IL6ST or CD130), LIF receptor (LIFR) and OSM receptor 
(OSMR) 100. These cytokines strongly active STAT3 and to a less extent other STAT 
family members (STAT1 and STAT5) 101. Phosphorylated STAT3 plays a central role in 
transcriptional regulation of a wide range of genes involved in cell growth, survival, 
differentiation, cell movement and pluripotency 101, 102.  
 
Figure 6. The JAK-STAT signalling pathway. Schematic and simplified illustration of the 
canonical JAK-STAT pathway. Janus kinase (JAK), signal transducer and activator of 
transcription (STAT), protein inhibitors of activated STAT (PIAS) and suppressors of cytokine 
signalling (SOCS) are shown. Cytokines bind to their receptors, which phosphorylate JAKs, 
causing activation of STATs. Dimerized phospho-STATs enter the nucleus, resulting in gene 
regulation. 
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   Various human malignancies are characterised by abnormal JAK-STAT activation 103. 
Somatically acquired JAK2 kinase point mutation (V617F) has been frequently found in 
haematological malignancies, such as myeloproliferative neoplasms and cancers arising 
from hematopoietic progenitor cells 104. In addition, large numbers of solid tumours 
exhibit activation of the JAK-STAT signalling pathway, including breast cancer 105, 
prostate cancer 106, lung cancer 107, glioblastoma 108 and malignant melanoma 109. In 
contrast to hematopoietic malignancies, solid tumours usually display constant 
activation of JAK1 and JAK2 as a result of alternative mechanisms including epigenetic 
silencing of negative regulators of JAKs, protein tyrosine phosphatases and suppressors 
of cytokine signalling, as well as an abnormal autocrine stimulation of cytokines and 
growth factors 110-112. STAT3 has also been observed to be constitutively activated in 
many tumours with important roles in different aspect of tumourigenesis, such as 
tumour survival, proliferation, angiogenesis, invasion, metastasis, drug resistance as well 
as CSCs. Hence, STAT3 is considered to be a suitable target for anti-cancer therapy 113-
117.  
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Aim 
 
The overall aims of this thesis were to investigate the role of the FUS-DDIT3 fusion 
oncogene in MLS by defining its regulatory and functional mechanisms, and to 
determine tumour heterogeneity, with focus on cancer stem cells and cell cycle 
regulation.  
 
Specific aims: 
Paper I: To determine the role and function of TP53 in MLS. 
Paper II: To determine the expression levels and regulatory mechanisms that 
control FUS-DDIT3 expression at both mRNA and protein level in 
MLS. 
Paper III: To define cell heterogeneity and identify cell subpopulations related to 
cell growth and cell division at single-cell level. 
Paper IV: To develop an approach that enables simultaneous DNA, mRNA and 
protein analysis of the same samples and to identify signalling 
pathways that regulate FUS-DDIT3 and FUS at both mRNA and 
protein level in MLS. 
Paper V: To define cancer stem cell features in MLS and how JAK-STAT 
signalling controls the number of cells with cancer stem cell 
properties. 
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Materials and methods  
Experimental model system and methods 
   In this thesis, we used cell lines and formalin-fixed paraffin-embedded tissue material. 
MLS derived cell lines 2645-94, 1765-92, 402-91 118, 119 and DL221 120, mesenchymal 
stem cells differentiated from an embryonic stem cell line121, breast cancer cell line 
MCF7 122, human fibrosarcoma cell line HT1080 123 as well as stably transfected 
subclones of the HT1080 cell line 59 were used. The following methods were used: cell 
culture, cell proliferation assay, flow cytometry, fluorescence-activated cell sorting, 
immunofluorescence, immunohistochemistry, immunoprecipitation, mass 
spectrometry, next generation sequencing, non-adherent condition assay, proximity 
ligation assay, scratch assay, side population analysis, single-cell analysis, transfections, 
quantitative real-time PCR and western blot analysis. 
Experimental details are outlined in each paper (I-V).   
Single-cell gene expression profiling 
   Cytogenetic characterisations and microsatellite studies have revealed large variability 
among individual cells within tumours 124. However, the limited understanding of 
tumour heterogeneity has been due to the lack of analytical techniques to study 
individual cells. Gene expression profiling, currently one of the most commonly applied 
techniques in tumour characterisation, is generally performed on a large pool of tumour 
cells. Consequently, samples constitute mixes of different cell types present in unknown 
proportions (Fig. 7). These studies will neither reveal heterogeneity within cell types nor 
important correlations in gene expression between cells. Cells in a population are in 
many aspects unique in their characteristics, even in a seemingly homogenous culture or 
tissue. Single-cell studies on both the protein and mRNA level show large cell-to-cell 
variation in both resting and stimulated states 125. This implies that data obtained from 
large pools of cells does not, and indeed, cannot, accurately reflect the behaviour of the 
individual cell. The need for single-cell gene expression analysis to understand tumour 
heterogeneity and the dynamic transition between cell states has been recognized for a 
long time, but the lack of sensitive analytical techniques to detect and quantify few 
transcripts has limited such measurements.  
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Figure 7. Cell and gene-expression heterogeneity. Single-cell analysis allows us to study 
differences between cell types as well as heterogeneity within defined cell types and/or cell 
states. Cases (A) and (B) show the same expression of X and Y transcripts at population level. 
However, single-cell analysis enables us to distinguish between the two cases. In case (A) 
transcripts X and Y are co-expressed in both cell types, while in case (B) X transcripts are 
only expressed in blue cells and Y transcripts are only expressed in yellow cells. 
   In this thesis, we have designed and developed gene expression assays for single-cell 
analysis. These assays include markers for cell proliferation, cell cycle regulation, TP53 
function, stemness, differentiation, cell signalling, and housekeeping functions. The 
experimental setup of single-cell qPCR is well established and has previously been 
reported in detail 126, 127. Briefly, single-cells were collected using fluorescence-activated 
cell sorting, followed by direct cell lysis, reverse transcription, preamplification and final 
analysis using quantitative real-time PCR (Fig. 8, paper II and III). In this thesis, single-
cell gene expression profiling in combination with proximity ligation assay was used to 
determine the expression of FUS-DDIT3 at both mRNA and protein level, as well as 
studying the effects of cell cycle phase and cell size on gene expression.  
 
Figure 8. Schematic overview of the single-cell gene expression analysis workflow. 
Individual cells are collected by fluorescent-activated cell sorting (FACS). Cells are lysed 
without extraction or purification and followed by, reverse transcription, preamlification and 
quantitative real-time PCR. Data analysis is performed with uni- and multivariate statistical 
tools. 
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Results and discussion 
Paper I: Normal and Functional TP53 in Genetically Stable Myxoid/Round 
Cell Liposarcoma  
   Translocations causing the FUS-DDIT3 and EWSR1-DDIT3 fusion oncogenes are 
the only chromosomal aberrations in the vast majority of MLS tumours. TERT- 
promoter mutations are detected in 70% of the cases and 10-15% are also carrying 
other mutations in genes such as PIK3CA and/or loss of PTEN 128. Except for these 
mutations, MLS tumours show few other changes and are considered as genetically 
stable. In some cases the fusion oncogene is the only mutation detected.  
   Inactivation of the tumour suppressor gene TP53 is a frequent event in 
tumourigenesis. The accumulation of TP53 expression as a result of its mutation is an 
independent marker for poor prognosis in several tumours 129. Hence, TP53 mutations 
have also been studied in MLS, however the results obtained with TP53 analysis have 
been inconsistent. Some studies have reported that TP53 mutation is related with poor 
prognosis and is associated with progressive disease 130. In contrast to these studies, our 
group and others have observed sporadic TP53 expression in MLS, which is not 
expected when TP53 is mutated, since TP53 mutations usually result in its 
overexpression. Instead, these data indicate that MLS has a normal TP53 function 131. A 
recent study also showed that the FUS-DDIT3 fusion oncogene formed MLS-like 
tumours in TP53-deficient mice only 132. These contradicting observations promoted us 
to study TP53 expression and function, using MLS cell lines as an experimental model 
system. 
   Here, we analysed four MLS-derived cell lines. Ion Torrent AmpliSeq sequencing 
using a cancer hotspot panel was performed to identify mutations. Data revealed no 
dysfunctional mutations among the 50 genes included in this panel covering the most 
common COSMIC (Catalogue of Somatic Mutations in Cancer) mutations, in three of 
the MLS cell lines. For the DL221 cell line we confirmed a previously known TP53 
mutation and a sequence variant for PIK3CA (data not reported). These data indicate 
an active and functional TP53 system in three out of four cell lines even after twenty 
years of in vitro cell culturing. The TP53 protein expression was analysed in all MLS cell 
lines by western blot and immunofluorescence showing that all cells expressed TP53 
protein. However, different sizes of the protein were observed in western blot data 
(Fig. 9). This may be explained by post-translational modifications reported for TP53, 
such as phosphorylation, methylation, ubiquitinylation and sumoylation. Analysis of 
TP53 function was performed using irradiation experiments with downstream western 
blot and immunofluorescence analyses. Two of the MLS cell lines (1765-92, 402-91) 
showed elevated TP53 expression and DL221 showed slightly elevated TP53 
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expression after irradiation, while MLS 2645-94 showed no or small regulation (Fig. 9). 
Low regulation of TP53 in MLS 2645-94 cell line may be explained by the fact that this 
cell line was immortalized using full length SV40 virus, while the MLS 1765-92 and 
402-91 cell lines only carry SV40 T-large antigen. Enhanced expression of TP53 after 
irradiation was also confirmed with immunofluorescence analysis. Functional TP53 in 
the MLS cell lines was also confirmed by activation of the TP53 target gene CDKN1A 
(P21) upon irradiation. To study if FUS-DDIT3 expression affected the TP53 
expression and its function, the fibroblast cell line HT1080 with and without stably 
transfected FUS-DDIT3 was analysed. Irradiation induced post-translational 
modification of TP53 in both HT1080 and HT1080 expressing FUS-DDIT3, indicating 
that FUS-DDIT3 does not affect TP53 function. Our results support that most MLS 
cases have a normal and functional TP53 system, which may explain why MLS tumours 
are sensitive to radiation and chemotherapy 133.  
 
Figure 9. TP53 expression in MLS. TP53 and CDKN1A (P21) expression in control and 
irradiated cells. The different TP53 bands correspond to different post-translationally 
modified TP53 forms. GAPDH was used as internal control. 
Paper II: Regulatory mechanisms, expression levels and proliferation 
effects of the FUS-DDIT3 fusion oncogene in liposarcoma 
   Myxoid liposarcoma is a unique tumour entity characterised by the FUS-DDIT3 
fusion oncogene that is observed in more than 90% of all cases. MLS rarely contains 
secondary mutations (paper I). The FUS-DDIT3 fusion oncogene encodes a chimeric 
transcription factor that is believed to be involved in tumour initiation and 
development.  
   To date, 12 different sequence variants of FUS-DDIT3 fusion oncogene are known 
134. Type I and II fusion oncoproteins are the most common isoforms caused by 
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different breakpoint locations of FUS, resulting in varying portions of the FUS protein 
being fused to the entire DDIT3 protein (Figs. 3B and 10A). Previous studies have 
shown distinct adipogenesis inhibitory activity between type I and II 135, 136. In addition, 
a recent study has shown different therapy response between isoforms of the fusion 
oncoprotein, which suggests a possible role of the FUS-DDIT3 isoforms in predicting 
a response to therapy 137. Hence, understanding the role of FUS-DDIT3 and its 
regulatory mechanism and functions can be used to develop better therapeutic and 
targeted treatments against the fusion oncoprotein.   
   Here, we studied the regulatory mechanisms that control the expression level of FUS-
DDIT3 at mRNA and protein level. We analysed four MLS-derived cell lines as a model 
system. They represent fusion oncogenes with three different breakpoints: Type I (MLS 
402-91 and DL221), Type II (MLS 2645-94) and Type VI (MLS 1765-92). Type II has 
the shortest FUS sequence part, while almost the entire FUS gene is fused with DDIT3 
in Type VI. We showed that the normal FUS is expressed to a higher degree than FUS-
DDIT3 at both mRNA and protein level (Fig. 10B, C). MLS 1765-92 with the longest 
FUS sequence showed the lowest FUS-DDIT3 mRNA expression. In contrast, FUS-
DDIT3 had the highest expression in MLS 1765-92 at protein level compared to the 
other isoforms. The stability of FUS-DDIT3 and FUS were determined at both mRNA 
and protein level. We showed that FUS-DDIT3 has a shorter half-life at both 
transcriptional and translational level compared to FUS. Only minor differences in 
mRNA half-life were observed between different FUS-DDIT3 variants, while the Type 
VI FUS-DDIT3 protein showed longer half-life compared to the other isoforms. The 
increased protein stability of Type VI FUS-DDIT3 may explain the high level of FUS-
DDIT3 protein in MLS 1765-92. We concluded that the FUS-DDIT3 mRNA stability 
was dependent on the DDIT3 sequence. In contrast, we could show that FUS-DDIT3 
protein stability was dependent on protein interactions through FUS rather than 
DDIT3 protein partners. Figure 10D shows that there is no correlation between FUS-
DDIT3 mRNA and protein expression, further indicating the importance of post-
transcriptional regulation of FUS-DDIT3 for its protein expression. 
   DDIT3 expression arrests cells in the G1/S phase, while FUS-DDIT3 expression 
enables cell proliferation 58. To determine the correlation between FUS-DDIT3 
expression and cell cycle regulation we performed single-cell analysis. Our data showed 
that cells containing high levels of FUS-DDIT3 protein displayed low expression of 
transcripts related to cell proliferation (Fig. 10E). In addition, forced overexpression of 
FUS-DDIT3 resulted in decreased cell proliferation. Others have shown that down-
regulation of FUS-DDIT3 also caused decreased cell proliferation 138. However, we 
have not been able to validate these findings. Altogether, our data show that the exact 
level of FUS-DDIT3 protein is important for cell proliferation.  
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Figure 10. FUS-DDIT3 and FUS expression and regulation. (A) FUS-DDIT3 gene 
structure. Different transcript variants of FUS-DDIT3 in MLS 2645-94, 402-91, 1765-92 and 
DL221 are shown. (B) Absolute quantification of FUS-DDIT3, FUS short (without 3’-
untranslated region (UTR)) and FUS long (with 3’-UTR region) mRNA variants showed 2.2-
3.6-fold lower expression of FUS-DDIT3 compared to FUS short. (C) Quantification of FUS-
DDIT3 protein expression compared to FUS showed 3.2-16 times lower expression. MLS 
1765-92 with the longest fusion oncoprotein showed higher expression than the two other 
isoforms. (D) Single-cell analysis of FUS-DDIT3 at mRNA compared to protein level 
displayed no correlation. Each dot represents an individual cell. (E) Principal component 
analysis of individual MLS 1765-92 cells. The FUS–DDIT3 protein and 43 mRNAs of which 
33 were proliferation-related transcripts, were analysed. The FUS-DDIT3 protein expression 
was negatively correlated with cell cycle related transcripts, i.e., cell proliferation. Each dot 
represents an individual cell. 
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Paper III: Cell cycle and cell size dependent gene expression reveals 
distinct subpopulations at single-cell level 
   Cell proliferation is one of the most fundamental biological processes, and it involves 
cell division and cell growth. Single-cell gene expression analysis opens up new 
possibilities to study and understand cell proliferation in detail. 
 
   In this article, single-cell analysis allowed us to assess the total transcript level 
between individual cells in a way that is not possible. Analysis of single MLS 402-91 
cells showed a correlation between total transcript levels and cell cycle phases, but not 
toward cell sizes (Fig. 11A). Principal component analysis of individual cells from 
different cell cycle phases displayed partly overlapping clusters. We performed 
supervised algorithms to classify cells (random forests) and to identify the subset of 
genes with highest predictive capacity (recursive feature elimination). By applying 
unsupervised algorithms and only analysing informative genes we were able to identify 
a subpopulation of cells (named G1´ subpopulation) with differentially expressed genes 
in MLS 402-91 (Fig. 11B) and MCF7. To visualize the cell cycle progression we 
calculated a cell cycle index based on gene expression (Fig. 11C). The index correlated 
with the G1, S and G2/M cell cycle phases. The G1´ subpopulation displayed the 
lowest cell cycle index, illustrating that these cells belong to the early G1 phase. The 
G1´ subpopulation in MLS 402-91 displayed a similar gene expression profile as the 
one identified in MCF7, except for the MCM6 gene. MCM6 was highly expressed in the 
G1´ MLS 402-91 subpopulation, while it was downregulated in MCF7. MCM6 belongs 
to the mini-chromosome maintenance (MCM) gene family that are essential DNA 
replication factors for initiation of DNA synthesis. In early G1, MCM proteins form 
heterohexamers with origin recognition complex (ORC), cell division cycle 6 (CDC6) 
and cdc10-dependent transcript 1 (CDT1) proteins to form the pre-replication 
complex. Interestingly, CDT1 was the second most upregulated gene in the G1´ MLS 
402-91 subpopulation (data not shown), indicating that the MCM complex might have 
a specific role in MLS. We also confirmed a heterogeneous MCM6 expression at 
protein level. Previous studies have shown that MCM proteins are overexpressed in 
multiple cancers and can provide important prognostic information in tumour biology 
139, 140. Further studies are required to determine the role of MCM in MLS.  
   Figure 11D shows that the gene expression of both FUS-DDIT3 and FUS in MLS 
402-91 scaled with cell cycle phase, similarly as the total transcript level and most other 
genes. Hence, we conclude that FUS-DDIT3 expression is not abnormally regulated 
throughout the cell cycle. In contrast, unpublished data indicate that the protein 
expression of FUS-DDIT3 is upregulated in the G2/M phase. In paper II, we showed 
that the level of FUS-DDIT3 protein was negatively correlated to the expression of 
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genes related to cell proliferation. Altogether, these data suggest that FUS-DDIT3 
protein, but not FUS-DDIT3 transcript, may play a direct role in cell proliferation and 
its regulation. This is further supported by the fact that FUS-DDIT3 interacts with 
Cdk2 through its DDIT3 part 141. In addition Cdk2 and Cdk4 with their associated 
cyclins, cyclin E and cyclin D1, are strongly overexpressed in MLS tumours 57. Other 
studies have also shown that the MCM complex and CDT1 are regulated by cyclin-
dependent kinases such as Cdk2 142, 143. Therefore, we speculate a possible link between 
FUS-DDIT3 and the MCM complex. However, the mechanisms by which FUS-
DDIT3 is controlling cell cycle needs further investigation. 
 
Figure 11. Cell-cycle dependent gene expression in MLS 402-91. (A)The total transcript 
level for small and large cells in the G1 (blue), S (gray), and G2/M (red) phases and double 
thymidine G1/S blocked cells (2xT block, black) are shown. B) An MLS 402- 91subpopulation 
(encircled) was identified using principal component analysis using genes identified by the 
random forest algorithm only. In the principal component analysis score, individual small 
(squares) and large (dots) MLS 402-91 cells in G1 (blue), S (gray), and G2/M (red) phase are 
shown. The position of a cell is defined by its gene expression profile. (C) The cell cycle index 
of each cell is shown in relation to its cell cycle phase. The G1’ subpopulation cells are 
shown in red. (D) FUS-DDIT3 and FUS expressions in small and large cells in each cell 
cycle phase. 
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Paper IV: Identification of inhibitors regulating cell proliferation and FUS-
DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA 
and protein analyses 
   Myxoid liposarcoma is a complex disease despite its simple genomic aberration (paper 
I). Most of the currently used clinically therapeutic agents such as trabectedin and 
doxorubicin are not effective for all patients. Persistence of the fusion oncoprotein 
after treatment indicates that these agents were not capable of eradicating the disease 
completely 144, 145. One possible strategy to target MLS in a specific manner is to target 
the fusion oncoprotein itself. Although the FUS-DDIT3 oncoprotein is present in the 
vast majority of MLS tumours, screening for drugs that directly or indirectly affect 
FUS-DDIT3 has never been employed on MLS cell lines to our knowledge. 
   In paper II we observed differential expression of FUS-DDIT3 at mRNA and protein 
level between MLS cell lines. In addition, the results from our single-cell analysis (paper 
II) together with our cell cycle analysis (paper III) showed association between FUS-
DDIT3 protein expression and cell proliferation. Thus, analysing the regulation of 
FUS-DDIT3 at both mRNA and protein level as well as cell proliferation facilitate the 
identification of novel therapeutic targets against the fusion oncoprotein. 
   To enable fast and simple analyses of cell proliferation, mRNA and protein we 
developed an extraction-free workflow, allowing specific DNA, RNA and protein to be 
measured with qPCR, reverse transcription qPCR and proximity ligation assay, 
respectively, in the same sample (Fig. 12). This approach was based on our experiences 
of analysing DNA, RNA and protein on direct lysed cells at single-cell level 146-148. Our 
data showed that RNA and DNA and protein could be accurately quantified using 
bovine serum albumin supplied in glycerol as direct lysis buffer. We also showed that 
both mRNA and protein data were correctly normalized using genomic DNA as 
reference when using direct lysis. 
   To identify potential signalling pathways involved in cell proliferation and regulation 
of FUS-DDIT3 and FUS at both mRNA and protein level, we performed a screen with 
70 kinase inhibitors in MLS 402-91 cells. Different ranges of growth arrest could be 
detected where the majority of the inhibitors reduced cell proliferation (Fig. 13A). 
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Figure 12. Schematic experimental workflow. Direct lysis of bulk samples followed by cell 
proliferation, mRNA and protein analysis. 
   FUS-DDIT3 and FUS mRNA expression showed strong correlation in all conditions. 
Based on our data in paper II, the 5’ FUS promoter rather than the DDIT3 sequence 
was important for the observed positive correlation (Fig. 13B) 149. FUS-DDIT3 protein 
expression more than FUS correlated more with its respective transcript level (Fig 13B, 
C). This observation can in part be explained by the fact that FUS protein has longer 
half-life than FUS-DDIT3 (paper II). Therefore, FUS-DDIT3 protein expression will 
adjust to altered gene expression faster than FUS, especially when FUS-DDIT3 is 
downregulated. Interestingly, FUS-DDIT3 expression showed a positive correlation 
with cell proliferation, while we in paper II showed that cells with ectopic FUS-DDIT3 
expression caused reduced cell proliferation. These data indicate that the exact level of 
FUS-DDIT3 is an important factor for cell proliferation in MLS cells. 
   Our kinase screening data demonstrated that the inhibitors that resulted in 
downregulation of the FUS-DDIT3 at both mRNA and protein level were mainly 
targeting JAK and GSK-3 kinases (Fig. 13). Inhibitors targeting tyrosine kinases 
belonging to the same signalling pathway showed different degree of effect on 
proliferation rates. For example, inhibitors number 2 (TG101348), 25 (ruxolitinib) and 
27 (barinitinib) all target the JAK2 kinase. TG101348 also maintained its proliferative 
effect even at the lower applied concentration, while the other two inhibitors showed 
no or minimal cell proliferation effect. The specificity of TG101348 and ruxolitinib 
have previously been examined using a near-kinome-wide survey 150. According to this 
study TG101348 inhibits the activity of more kinases as off-targets compared to 
ruxolitinib. Therefore, it is likely that the proliferative effect of TG101348 is more 
related to off-target inhibition than to JAK2 inhibition. It has been suggested that the 
lack of specificity may not always be a disadvantage in therapy. However, lack of target 
specificity may result in unknown side effects and is therefore usually an unwanted 
feature in therapy 151. 
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Figure 13. Kinase inhibitor screening. MLS 402-91 cells were treated with 70 kinase 
inhibitors compared to treatment control (DMSO) and untreated cells. (A) Proliferation was 
analysed by measuring gDNA. (B) Pairwise FUS-DDIT3 (left) and FUS (right) mRNA 
regulation are shown for each inhibitor. Inhibitors 1 to 7 are eliminated due to lack of 
reliable data, because of cell death. (C) Pairwise FUS-DDIT3 (left) and FUS (right) protein 
regulation are shown for each inhibitor. Inhibitors 1 to 7 are eliminated due to lack of 
reliable data, because of cell death. Data are compared to the DMSO controls in each data 
set. Mean ± SEM is shown, n=4. 
26 
 
Paper V: JAK-STAT signalling controls cancer stem cell properties in 
myxoid liposarcoma 
   In spite of extensive efforts in conventional and targeted chemotherapeutic 
treatments, therapy relapses occur in clinical oncology. Recent studies suggest that the 
functional and molecular properties of small subpopulations of cancer cells play an 
important role in therapy resistance and tumour relapse 64, 152. These cells usually 
possess stem-like characteristics and are referred to as CSCs. In this study we studied 
CSC properties, including chemotherapy resistance, in three MLS cell lines. We showed 
that the MLS cell lines were capable of forming tumour spheres, i.e., sarcospheres, a 
feature specific for CSCs (Fig. 14A). Although various surface markers have been used 
to identify and isolate CSC subpopulations in epithelial tumours, to date no specific and 
useful surface marker has been discovered in MLS. Instead, we used the functional side 
population discrimination assay (Hoechst staining) to identify subpopulation of cells 
that are able to efflux dyes, an additional property associated with CSCs. 
   The overall response of MLS to single chemotherapy treatment, such as doxorubicin 
and trabectedin, is about 50% 153-155. A hypothesis that may explain therapy resistance 
in patients is the presence of drug resistant CSC subpopulations. Our data displayed a 
large association between the sarcosphere formation capacity and the IC50 value of 
doxorubicin. Furthermore, we observed increased numbers of sarcospheres and side 
population fractions in doxorubicin treated cells. Interestingly, the cells that formed the 
least number of sarcospheres (MLS 402-91) displayed almost no side population cells 
and were the most sensitive to doxorubicin treatment. Altogether, these data 
demonstrate the existence of subpopulations with CSC features in MLS. In agreement 
with previous studies, we showed that doxorubicin mainly kills sensitive and 
proliferative cells, resulting in the enrichment of therapy resistant cells with CSC 
properties 156, 157.  
   Next, we showed that the JAK-STAT signalling controls the number of cells with 
CSC characteristics in MLS. Dysregulation of the JAK-STAT signalling pathway upon 
constant activation of STAT3 has been shown in tumour development and CSC 
maintenance in several tumour entities, including gliobastoma 158, lung cancer 159, 160 and 
colon cancer 161. In MLS cell lines, sarcosphere formation was decreased when the 
activation of STAT3 was blocked using ruxolitinib (JAK1/2 inhibitor) (Fig. 14B). MLS 
1765-92, with the highest expression of phosphorylated STAT3 under normal growth 
conditions generated the largest sarcosphere number reduction, showing that the level 
of phosphorylated STAT3 correlated to the number of cells with CSC features in 
respective MLS cell line. In a previous study, we have showed that elevated expression 
of IL6 is observed in FUS-DDIT3 expressing cell lines 162. IL6 belongs to the IL6-type 
cytokine family that mainly act via homo- or hetero-dimerization of GP130, LIF and 
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IL6 receptors 100, 101. Protein analysis of LIF, GP130 and IL6 receptors showed strong, 
intermediate and almost no expression, respectively. Moreover, LIF mediated the 
induction of phosphorylated STAT3 and increased the number of formed sarcospheres 
(Fig. 14C). Ruxolitinib inhibited the LIF-induced stimulation, suggesting that the JAK-
STAT signalling mediate the maintenance of cells with CSC properties via the 
LIF/JAK1/2/STAT3 signalling pathway (Fig. 14D). 
   Finally we evaluated whether JAK-STAT signalling could be a potential therapeutic 
target that could be used in combination with doxorubicin. The combined treatment of 
doxorubicin and ruxolitinib resulted in reduction of formed sarcospheres compared to 
cells treated with doxorubicin only. However, the combined treatment did not eliminate 
all cells with capacity to form sarcospheres (Fig. 14E). These observations indicate the 
existence of a subpopulation of cells with CSC features that may resist therapy through 
another mechanism other than JAK-STAT signalling. In summary, our data indicates 
that MLS treatment may be improved through a combined doxorubicin and ruxolitinib 
treatment. Further studies, including in vivo experiments, are needed to determine the 
full potential of applying JAK-STAT inhibition to treat MLS.  
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Figure 14. CSC properties and JAK-STAT signalling in MLS. (A) Sarcosphere formation 
efficiency of MLS 2645-94, 1765-92 and 402-91cells calculated as the fraction of formed 
spheres in relation to the total number of seeded cells. Mean ± SEM is shown, n = 3. (B) 
Ruxolitinib inhibition of JAK1/2. Western blot analysis of phosphorylated STAT3 (p-STAT3) 
and STAT3 compared to untreated control (DMSO) cells. GAPDH was used as an internal 
protein loading control. (C) LIF induced cancer stem cell properties in MLS. Sarcosphere 
formation capacity of MLS cells treated with LIF. Three independent experiments were 
performed (orange, red and blue). For each individual experiment three technical replicates 
were performed. Mean ± SEM is shown, paired student t-test, *p< 0.05, ** p< 0.01. (D) LIF 
acts through JAK1/2. Western blot analysis of p-STAT3 in MLS cells treated with LIF, 
ruxolitinib, and LIF in combination with ruxolitinib. GAPDH was used as an internal protein 
loading control. (E) Sarcosphere forming capacity of MLS cells when treated with 
doxorubicin and ruxolitinib in combination. Three independent experiments (orange, red and 
blue) were performed. For each individual experiment, three technical replicates were 
performed. Mean ± SEM is shown, paired student t-test, *p< 0.05, ** p< 0.01. 
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Conclusions 
Paper I 
In conclusion, our sequencing data of long-term cultured MLS cell lines confirms that 
MLS cells are genetically stable with no additional mutations accumulating even after 
long-term passaging. Furthermore, our data show that MLS has a functional TP53 
system, which is consistent with the low numbers of secondary mutations observed in 
this tumour entity. 
Paper II 
In conclusion, we found that the expression of FUS-DDIT3 is regulated by the FUS 
promotor and its stability was dependent on the DDIT3 sequence at mRNA level. At 
protein level, FUS-DDIT3 stability was dependent on protein interactions through the 
FUS rather than the DDIT3 protein. Furthermore, cell proliferation was negatively 
correlated to FUS-DDIT3 protein expression. Detailed characterisation of FET fusion 
oncogenes and precise understanding of their regulation is important when defining the 
role of FUS-DDIT3 in tumour initiation and development. In the long-term perspective 
this knowledge may be used to develop tumour specific treatments targeting the fusion 
oncoprotein itself or biological processes directly associated with FUS-DDIT3 
function.    
Paper III 
In conclusion, we provide useful experimental approaches and bioinformatics tools to 
identify informative and predictive genes at the single-cell level, which opens up new 
means to describe and understand cell proliferation and subpopulation dynamics. By 
implementing suitable analytical tools, we were able to identify potential biomarkers 
that are differentially expressed throughout the cell cycle in MLS. This allowed us to 
identify a G1 subpopulation with a distinct gene expression profile that was specific to 
MLS. Detailed analysis of individual cells in different proliferative states opens up new 
possibilities to identify cell cycle abnormalities and the role of FUS-DDIT3 in this 
biological process that is essential in MLS development. Identification of tumour-
specific biomarkers opens up new possibilities to develop targeted therapies. 
Paper IV 
We developed an extraction-free workflow that enabled DNA, mRNA and protein 
analysis in the same sample. This approach was applied to study how well-characterised 
kinase inhibitors regulated cell proliferation and expression of FUS-DDIT3 and FUS at 
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both mRNA and protein level. We identified a number of previously unknown 
pathways, including JAK-STAT and GSK signalling pathways that regulated the 
expression of FUS-DDIT3 at both transcriptional and translational level. FUS-DDIT3 
itself and its functions are potential therapy targets specific for MLS. 
Paper V 
In conclusion, we found that MLS contained subpopulation of cells with CSC 
properties, including chemotherapy resistance. We also showed that JAK-STAT 
signalling controls the number of cells with CSC features. More specifically we show 
that LIF act through JAK1/2 and STAT3 signalling. Furthermore, our data showed 
that the inhibition of JAK-STAT signalling in combination with chemotherapy 
displayed synergistic treatment effects. Better understanding and characterisation of 
CSCs in MLS will provide new means to identify novel targets and to develop specific 
therapies that target truly malignant subpopulations of tumour cells.   
  
Future perspectives 
Notwithstanding continuous progress in treating MLS, existing therapies suffer from a 
major flaw; they do not target cells with CSC properties. Unique features of CSCs, and 
theoretically possible targets for specific therapy, include self-renewal, tumourigenicity, 
multi-lineage differentiation, and increased resistance to radio- and chemotherapy-
induced cell death. Thus, cells with CSC features are critical targets in cancer therapy. 
Little is known about CSCs and fusion oncoproteins in MLS despite the fact that they 
are causal factors in tumourigenesis. Current experimental approaches to identify and 
characterise rare subpopulation of cells are technically challenging. Thus innovative 
approaches, such as single-cell analysis, are needed to decipher the nature of tumour 
subpopulations. Furthermore, expression profiling of individual cells opens up new 
possibilities for precise understanding of fusion oncogenes and their specific functions. 
By defining CSCs at the molecular level and determining the function of fusion 
oncogenes, we will be able to develop specific treatments that ultimately will increase 
the survival and life quality of patients diagnosed with MLS.      
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